INBS
Intelligent Bio Solutions Inc.
NASDAQ: INBS · HEALTHCARE · MEDICAL DEVICES
$2.05
-0.97% today
Updated 2026-09-15
Market cap
$7.48M
P/E ratio
—
P/S ratio
1.65x
EPS (TTM)
$-8.44
Dividend yield
—
52W range
$2 – $25
Volume
0.2M
WallStSmart proprietary scores
36
out of 100
Grade: D
Sell
Investment rating
8.0
Growth
A5.0
Quality
C+2.0
Profitability
F4.7
Valuation
C4/9
Piotroski F-Score
Moderate
-11.2
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →252 stocks currently score above 75
Price targets
Analyst target
$12.00
+485.37%
12-Month target
—
—
Intrinsic (DCF)
$4.79
Margin of safety
-9.60%
Price chart
Stock snapshot
Strengths
+ Revenue growth 35.80% QoQ
+ Debt/equity 0.33x — low leverage
Risks
- Altman Z -11.18 — distress zone
- Thin margins at -294.90%
- Negative free cash flow $-3.18M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|
| Revenue | $1.26M | $3.11M | $3.05M | $4.22M | $4.22M |
| Net income | $-10.63M | $-10.16M | $-10.57M | $-12.43M | $-3.91M |
| EPS | — | — | — | — | $-8.44 |
| Free cash flow | $-7.88M | $-9.79M | $-9.91M | $-12.05M | $-3.18M |
| Profit margin | -845.89% | -326.40% | -346.23% | -294.91% | -294.90% |
Peer comparison
Smart narrative
Intelligent Bio Solutions Inc. trades at $2.05. Our Smart Value Score of 36/100 indicates the stock is weak. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of -11.18, it sits in the distress. TTM revenue stands at $4.22M. with profit margins at -294.90%. Our DCF model estimates intrinsic value at $4.79.
Frequently asked questions
What is Intelligent Bio Solutions Inc.'s stock price?
Intelligent Bio Solutions Inc. (INBS) trades at $2.05, on a P/S of 1.7x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Intelligent Bio Solutions Inc. overvalued?
Intelligent Bio Solutions Inc. carries a Smart Value Score of 36/100 (Grade D), which we rate Sell. That score blends growth, quality, and valuation into one read. On valuation specifically, our conservative DCF puts intrinsic value at $4.79 against the $2.05 price, so on cash flow terms the market is paying a premium for Intelligent Bio Solutions Inc.'s growth. The Sell rating reflects that growth and quality, while the DCF flags that the price already assumes a lot.
What is the price target of Intelligent Bio Solutions Inc. (INBS)?
The 12-month analyst consensus target is $12.00, about 485.4% above the current $2.05. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the intrinsic value of Intelligent Bio Solutions Inc. (INBS)?
Our DCF model estimates intrinsic value at $4.79, a -9.6% margin of safety versus today's $2.05. Intrinsic value is what the projected cash flows are worth today. A negative reading means the price is running ahead of that conservative estimate, leaving little downside cushion if growth slows.
What is Intelligent Bio Solutions Inc.'s revenue?
Intelligent Bio Solutions Inc.'s trailing twelve-month revenue is $4.22M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Intelligent Bio Solutions Inc.'s Altman Z-Score is -11.18, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryMEDICAL DEVICES
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio1.65x
ROE-170.20%
Beta4.21
50D MA$2.20
200D MA$4.47
Shares out0.00B
Float0.00B
Short ratio—
Avg volume0.2M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—